Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
47.56
+1.69 (3.68%)
At close: Jan 17, 2025, 4:00 PM
47.46
-0.10 (-0.21%)
After-hours: Jan 17, 2025, 6:01 PM EST
Twist Bioscience Revenue
In the fiscal year ending September 30, 2024, Twist Bioscience had annual revenue of $312.97M with 27.69% growth. Twist Bioscience had revenue of $84.71M in the quarter ending September 30, 2024, with 26.53% growth.
Revenue (ttm)
$312.97M
Revenue Growth
+27.69%
P/S Ratio
8.82
Revenue / Employee
$339,083
Employees
923
Market Cap
2.83B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
TWST News
- 4 weeks ago - Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Twist Bioscience: Path To Profitability Beginning To Take Shape - Seeking Alpha
- 2 months ago - Twist Bioscience: A Post-Earnings Assessment - Seeking Alpha
- 2 months ago - Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps - Benzinga
- 2 months ago - Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results - Business Wire
- 2 months ago - Twist Bioscience to Present at 7th Annual Evercore HealthCONx Conference - Business Wire
- 2 months ago - Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy' - Seeking Alpha